Celgene's Revlimid improves survival in blood cancer patients
July 11 (Reuters) - Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in blood cancer patients.
The drug was tested in patients with newly diagnosed multiple myeloma, and showed a statistically significant improvement in survival, without the cancer worsening.
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- Probe: Athletes took fake classes at University of North Carolina
- Canada's Harper pledges tougher security laws after attack |
- Man arrested after jumping White House fence, causing lockdown
- Some U.S. hospitals weigh withholding care to Ebola patients